Literature DB >> 23664324

A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints.

Awad A Ahmed1, Brian Egleston, Pino Alcantara, Linna Li, Alan Pollack, Eric M Horwitz, Mark K Buyyounouski.   

Abstract

BACKGROUND: There are no well-established normal tissue sparing dose-volume histogram (DVH) criteria that limit the risk of urinary toxicity from prostate radiation therapy (RT). The aim of this study was to determine which criteria predict late toxicity among various DVH parameters when contouring the entire solid bladder and its contents versus the bladder wall. The area under the histogram curve (AUHC) was also analyzed. METHODS AND MATERIALS: From 1993 to 2000, 503 men with prostate cancer received 3-dimensional conformal RT (median follow-up time, 71 months). The whole bladder and the bladder wall were contoured in all patients. The primary endpoint was grade ≥2 genitourinary (GU) toxicity occurring ≥3 months after completion of RT. Cox regressions of time to grade ≥2 toxicity were estimated separately for the entire bladder and bladder wall. Concordance probability estimates (CPE) assessed model discriminative ability. Before training the models, an external random test group of 100 men was set aside for testing. Separate analyses were performed based on the mean age (≤ 68 vs >68 years).
RESULTS: Age, pretreatment urinary symptoms, mean dose (entire bladder and bladder wall), and AUHC (entire bladder and bladder wall) were significant (P<.05) in multivariable analysis. Overall, bladder wall CPE values were higher than solid bladder values. The AUHC for bladder wall provided the greatest discrimination for late bladder toxicity when compared with alternative DVH points, with CPE values of 0.68 for age ≤68 years and 0.81 for age >68 years.
CONCLUSION: The AUHC method based on bladder wall volumes was superior for predicting late GU toxicity. Age >68 years was associated with late grade ≥2 GU toxicity, which suggests that risk-adapted dose constraints based on age should be explored.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23664324      PMCID: PMC3860375          DOI: 10.1016/j.ijrobp.2013.03.020

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial.

Authors:  M R Storey; A Pollack; G Zagars; L Smith; J Antolak; I Rosen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

2.  Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.

Authors:  L J Boersma; M van den Brink; A M Bruce; T Shouman; L Gras; A te Velde; J V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-04-01       Impact factor: 7.038

3.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

Authors:  J D Cox; J Stetz; T F Pajak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

4.  Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.

Authors:  E M Horwitz; A L Hanlon; W H Pinover; P R Anderson; G E Hanks
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

5.  Conformal irradiation of concave-shaped PTVs in the treatment of prostate cancer by simple 1D intensity-modulated beams.

Authors:  C Fiorino; S Broggi; D Corletto; G M Cattaneo; R Calandrino
Journal:  Radiother Oncol       Date:  2000-04       Impact factor: 6.280

6.  Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer.

Authors:  Eugene H Huang; Alan Pollack; Larry Levy; George Starkschall; Lei Dong; Isaac Rosen; Deborah A Kuban
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

7.  Inverse and forward optimization of one- and two-dimensional intensity-modulated radiation therapy-based treatment of concave-shaped planning target volumes: the case of prostate cancer.

Authors:  Daniela Corletto; Mauro Iori; Marta Paiusco; Lorenzo Brait; Sara Broggi; Giovanni Ceresoli; Cinzia Iotti; Riccardo Calandrino; Claudio Fiorino
Journal:  Radiother Oncol       Date:  2003-02       Impact factor: 6.280

Review 8.  Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.

Authors:  Gert De Meerleer; Luc Vakaet; Sabine Meersschout; Geert Villeirs; Antony Verbaeys; Wim Oosterlinck; Wilfried De Neve
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

9.  Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.

Authors:  Daniel E Spratt; Xin Pei; Josh Yamada; Marisa A Kollmeier; Brett Cox; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-12       Impact factor: 7.038

10.  Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer.

Authors:  J V Lebesque; A M Bruce; A P Kroes; A Touw; R T Shouman; M van Herk
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-12-01       Impact factor: 7.038

View more
  7 in total

1.  Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.

Authors:  A Zapatero; M Roch; D Büchser; P Castro; L Fernández-Banda; G Pozo; O Liñán; C Martin de Vidales; A Cruz-Conde; F García-Vicente
Journal:  Clin Transl Oncol       Date:  2017-04-03       Impact factor: 3.405

2.  Delineating the inner bladder surface using uniform contractions from the outer surface under variable bladder filling conditions.

Authors:  Tara Rosewall; Andrew Bayley; Charles Catton; Peter Chung; Geoffrey Currie; Robert Heaton; Janelle Wheat; Michael Milosevic
Journal:  Br J Radiol       Date:  2015-07-24       Impact factor: 3.039

3.  Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.

Authors:  Jennifer A Woo; Leonard N Chen; Aditi Bhagat; Eric K Oermann; Joy S Kim; Rudy Moures; Thomas Yung; Siyuan Lei; Brian T Collins; Deepak Kumar; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Front Oncol       Date:  2014-05-26       Impact factor: 6.244

4.  Long-term outcomes in patients treated with proton therapy for localized prostate cancer.

Authors:  Masaru Takagi; Yusuke Demizu; Kazuki Terashima; Osamu Fujii; Dongcun Jin; Yasue Niwa; Takashi Daimon; Masao Murakami; Nobukazu Fuwa; Tomoaki Okimoto
Journal:  Cancer Med       Date:  2017-09-06       Impact factor: 4.452

5.  Incidence of genitourinary complications following radiation therapy for localised prostate cancer.

Authors:  Rowan V David; Arman A Kahokehr; Jason Lee; David I Watson; John Leung; Michael E O'Callaghan
Journal:  World J Urol       Date:  2022-08-11       Impact factor: 3.661

6.  Urinary toxicity after salvage re-irradiation for prostate cancer local failure after definitive radiotherapy: a clinical and dosimetric prognostic factors analysis.

Authors:  Giovanna Dipasquale; Thomas Zilli; Claudio Fiorino; Vérane Achard; Michel Rouzaud; Raymond Miralbell
Journal:  J Contemp Brachytherapy       Date:  2022-06-14

7.  Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients.

Authors:  Wouter Schaake; Arjen van der Schaaf; Lisanne V van Dijk; Alfons C M van den Bergh; Johannes A Langendijk
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.